Close Menu

NEW YORK – Lucid Diagnostics, a PAVmed subsidiary, said Thursday that it has received breakthrough device designation from the US Food and Drug Administration for a test to detect esophageal dysplasia and potential cancer risk.

Called the EsoGuard Esophageal DNA Test, the assay is meant to be performed on esophageal samples collected using the firm's EsoCheck Cell Collection Device in a well-defined group of patients at elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease, or GERD.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.